Category Archives: Antibiotics

Sanofi faces criticism at lung conference

Treatment Action Campaign; December 4, 2015. CApe Town – Activists at the 46th Union World Conference on Lung Health demanded that pharmaceutical company Sanofi be held accountable for endangering failing to provide life-saving products to people and children living with TB and … Continue reading

Posted in Antibiotics, Tuberculosis (TB) | Leave a comment

First new TB drugs in half a century reach just 2% of people who need them

MSF; December 3, 2015. Cape Town – Nearly three years since the first of two new tuberculosis (TB) medicines became available, the drugs remain out of reach for people who need them, with just two percent of people eligible for these treatments … Continue reading

Posted in Antibiotics, Pricing, Tuberculosis (TB) | Leave a comment

Tackling Antimicrobial Resistance Is an Area BRIC Countries Can Lead the World – They Must Take This Opportunity

Huffington Post; November 12, 2015. Brazil, India, Russia and China have gone through a period of rapid economic development, making them important global players in the 21st century. However, they are also the countries that might be affected most severely by growing antimicrobial … Continue reading

Posted in Antibiotics, BRICS, Innovation | Leave a comment

Pay big pharma to solve antibiotics crisis, says UK government review

The Guardian; Pharmaceutical companies should be given cash incentives of up to $3bn to find and develop new antibiotics desperately needed to keep infections at bay, according to a UK government review. Jim O’Neill, the economist and former chair of … Continue reading

Posted in Antibiotics, Delinkage, Innovation | Leave a comment

UK/China fund on antimicrobial resistance to launch

onmedica; Ocober 26, 2015. By Adrian O’Dowd. A joint fund between the UK and China is to be launched to boost a global response to the growing problem of antimicrobial resistance (AMR) through dedicated research.

Posted in Antibiotics, Innovation | Leave a comment

Chatham House Report On Antibiotics Gives Evidence For Drug R&D Delinkage

Source: IP watch, October 9, 2015 A new report from Chatham House presenting suggestions for novel business models for antibiotics calls for models in which the return on investment in research and development is not dependent on the volume of … Continue reading

Posted in Antibiotics, Delinkage, Innovation, Tuberculosis (TB) | Leave a comment